Evaluation of metformin in early breast cancer: A modification of the traditional paradigm for clinical testing of anti-cancer agents

Pamela J. Goodwin, Vuk Stambolic, Julie Lemieux, Bingshu E. Chen, Wendy R. Parulekar, Karen A. Gelmon, Dawn L. Hershman, Timothy James Hobday, Jennifer A. Ligibel, Ingrid A. Mayer, Kathleen I. Pritchard, Timothy J. Whelan, Priya Rastogi, Lois E. Shepherd

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

Metformin, an inexpensive oral agent commonly used to treat type 2 diabetes, has been garnering increasing attention as a potential anti-cancer agent. Preclinical, epidemiologic, and clinical evidences suggest that metformin may reduce overall cancer risk and mortality, with specific effects in breast cancer. The extensive clinical experience with metformin, coupled with its known (and modest) toxicity, has allowed the traditional process of drug evaluation to be shortened. We review the rationale for a modified approach to evaluation and outline the key steps that will optimize development of this agent in breast cancer, including discussion of a Phase III adjuvant trial (NCIC MA.32) that has recently been initiated.

Original languageEnglish (US)
Pages (from-to)215-220
Number of pages6
JournalBreast Cancer Research and Treatment
Volume126
Issue number1
DOIs
StatePublished - Feb 2011

Fingerprint

Metformin
Breast Neoplasms
Neoplasms
Drug Evaluation
Type 2 Diabetes Mellitus
Mortality

Keywords

  • Adjuvant
  • Breast cancer
  • Clinical testing
  • Metformin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Evaluation of metformin in early breast cancer : A modification of the traditional paradigm for clinical testing of anti-cancer agents. / Goodwin, Pamela J.; Stambolic, Vuk; Lemieux, Julie; Chen, Bingshu E.; Parulekar, Wendy R.; Gelmon, Karen A.; Hershman, Dawn L.; Hobday, Timothy James; Ligibel, Jennifer A.; Mayer, Ingrid A.; Pritchard, Kathleen I.; Whelan, Timothy J.; Rastogi, Priya; Shepherd, Lois E.

In: Breast Cancer Research and Treatment, Vol. 126, No. 1, 02.2011, p. 215-220.

Research output: Contribution to journalArticle

Goodwin, PJ, Stambolic, V, Lemieux, J, Chen, BE, Parulekar, WR, Gelmon, KA, Hershman, DL, Hobday, TJ, Ligibel, JA, Mayer, IA, Pritchard, KI, Whelan, TJ, Rastogi, P & Shepherd, LE 2011, 'Evaluation of metformin in early breast cancer: A modification of the traditional paradigm for clinical testing of anti-cancer agents', Breast Cancer Research and Treatment, vol. 126, no. 1, pp. 215-220. https://doi.org/10.1007/s10549-010-1224-1
Goodwin, Pamela J. ; Stambolic, Vuk ; Lemieux, Julie ; Chen, Bingshu E. ; Parulekar, Wendy R. ; Gelmon, Karen A. ; Hershman, Dawn L. ; Hobday, Timothy James ; Ligibel, Jennifer A. ; Mayer, Ingrid A. ; Pritchard, Kathleen I. ; Whelan, Timothy J. ; Rastogi, Priya ; Shepherd, Lois E. / Evaluation of metformin in early breast cancer : A modification of the traditional paradigm for clinical testing of anti-cancer agents. In: Breast Cancer Research and Treatment. 2011 ; Vol. 126, No. 1. pp. 215-220.
@article{9c5bbfd8e6944ae8b97aa66167abdc5a,
title = "Evaluation of metformin in early breast cancer: A modification of the traditional paradigm for clinical testing of anti-cancer agents",
abstract = "Metformin, an inexpensive oral agent commonly used to treat type 2 diabetes, has been garnering increasing attention as a potential anti-cancer agent. Preclinical, epidemiologic, and clinical evidences suggest that metformin may reduce overall cancer risk and mortality, with specific effects in breast cancer. The extensive clinical experience with metformin, coupled with its known (and modest) toxicity, has allowed the traditional process of drug evaluation to be shortened. We review the rationale for a modified approach to evaluation and outline the key steps that will optimize development of this agent in breast cancer, including discussion of a Phase III adjuvant trial (NCIC MA.32) that has recently been initiated.",
keywords = "Adjuvant, Breast cancer, Clinical testing, Metformin",
author = "Goodwin, {Pamela J.} and Vuk Stambolic and Julie Lemieux and Chen, {Bingshu E.} and Parulekar, {Wendy R.} and Gelmon, {Karen A.} and Hershman, {Dawn L.} and Hobday, {Timothy James} and Ligibel, {Jennifer A.} and Mayer, {Ingrid A.} and Pritchard, {Kathleen I.} and Whelan, {Timothy J.} and Priya Rastogi and Shepherd, {Lois E.}",
year = "2011",
month = "2",
doi = "10.1007/s10549-010-1224-1",
language = "English (US)",
volume = "126",
pages = "215--220",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Evaluation of metformin in early breast cancer

T2 - A modification of the traditional paradigm for clinical testing of anti-cancer agents

AU - Goodwin, Pamela J.

AU - Stambolic, Vuk

AU - Lemieux, Julie

AU - Chen, Bingshu E.

AU - Parulekar, Wendy R.

AU - Gelmon, Karen A.

AU - Hershman, Dawn L.

AU - Hobday, Timothy James

AU - Ligibel, Jennifer A.

AU - Mayer, Ingrid A.

AU - Pritchard, Kathleen I.

AU - Whelan, Timothy J.

AU - Rastogi, Priya

AU - Shepherd, Lois E.

PY - 2011/2

Y1 - 2011/2

N2 - Metformin, an inexpensive oral agent commonly used to treat type 2 diabetes, has been garnering increasing attention as a potential anti-cancer agent. Preclinical, epidemiologic, and clinical evidences suggest that metformin may reduce overall cancer risk and mortality, with specific effects in breast cancer. The extensive clinical experience with metformin, coupled with its known (and modest) toxicity, has allowed the traditional process of drug evaluation to be shortened. We review the rationale for a modified approach to evaluation and outline the key steps that will optimize development of this agent in breast cancer, including discussion of a Phase III adjuvant trial (NCIC MA.32) that has recently been initiated.

AB - Metformin, an inexpensive oral agent commonly used to treat type 2 diabetes, has been garnering increasing attention as a potential anti-cancer agent. Preclinical, epidemiologic, and clinical evidences suggest that metformin may reduce overall cancer risk and mortality, with specific effects in breast cancer. The extensive clinical experience with metformin, coupled with its known (and modest) toxicity, has allowed the traditional process of drug evaluation to be shortened. We review the rationale for a modified approach to evaluation and outline the key steps that will optimize development of this agent in breast cancer, including discussion of a Phase III adjuvant trial (NCIC MA.32) that has recently been initiated.

KW - Adjuvant

KW - Breast cancer

KW - Clinical testing

KW - Metformin

UR - http://www.scopus.com/inward/record.url?scp=79151478459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79151478459&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-1224-1

DO - 10.1007/s10549-010-1224-1

M3 - Article

C2 - 20976543

AN - SCOPUS:79151478459

VL - 126

SP - 215

EP - 220

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -